These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 671453)

  • 1. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
    Hatheway GJ; Hansch C; Kim KH; Milstein SR; Schmidt CL; Smith RN; Quinn FR
    J Med Chem; 1978 Jun; 21(6):563-74. PubMed ID: 671453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
    Hansch C; Hatheway GJ; Quinn FR; Greenberg N
    J Med Chem; 1978 Jun; 21(6):574-7. PubMed ID: 671454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of antitumor activity of 1-[N, N-bis(2-chloroethyl) sulfamoylphenyl]-3,3-dialkyltriazenes.
    Lalezari I; Afghahi F
    J Pharm Sci; 1975 Apr; 64(4):698-9. PubMed ID: 1142087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and antitumor activity of derivatives of 1-phenyl-3,3-dimethyltriazene.
    Lin YT; Loo TL
    J Med Chem; 1972 Feb; 15(2):201-3. PubMed ID: 5008242
    [No Abstract]   [Full Text] [Related]  

  • 5. Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity study.
    Venger BH; Hansch C; Hatheway GJ; Amrein YU
    J Med Chem; 1979 May; 22(5):473-6. PubMed ID: 379331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antitumor activity of alkyltriazenopyrazoles.
    Zakharieva RD; Spassova MK; Karaivanova MC; Golovinsky EV
    Arzneimittelforschung; 1984; 34(6):661-3. PubMed ID: 6541485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
    Hansch C; Leo A; Schmidt C; Jow PY; Montgomery JA
    J Med Chem; 1980 Oct; 23(10):1095-101. PubMed ID: 7420354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
    Lin AJ; Loo TL
    J Med Chem; 1978 Mar; 21(3):268-72. PubMed ID: 628002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ames test and antitumor activity of 1-(X-phenyl)-3,3-dialkyltriazenes. Quantitative structure-activity studies based upon molecular shape analysis.
    Hopfinger AJ; Potenzone R
    Mol Pharmacol; 1982 Jan; 21(1):187-95. PubMed ID: 7132958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 5-(3, 3-disubstituted-1-triazenyl) imidazole-4-carbonitriles.
    Shealy YF; O'Dell CA
    J Pharm Sci; 1975 Jun; 64(6):954-6. PubMed ID: 1133749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative structure-activity relationships (QSAR) for 9-anilinoacridines: a comparative analysis.
    Gao H; Denny WA; Garg R; Hansch C
    Chem Biol Interact; 1998 Nov; 116(3):157-80. PubMed ID: 9920460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-activity relationships of antineoplastic drugs: nitrosoureas and triazenoimidazoles.
    Hansch C; Smith N; Engle R; Wood H
    Cancer Chemother Rep; 1972 Aug; 56(4):443-56. PubMed ID: 5081587
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
    Wilman DE; Cox PJ; Goddard PM; Hart LI; Merai K; Newell DR
    J Med Chem; 1984 Jul; 27(7):870-4. PubMed ID: 6737430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triazenes of phenylbutyric, hydrocinnamic, phenoxyacetic, and benzoylglutamic acid derivatives.
    Shealy YF; Krauth CA; Opliger CE; Guin HW; Laster WR
    J Pharm Sci; 1971 Aug; 60(8):1192-8. PubMed ID: 5166659
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential anticancer agents. XXII. Pharmacological properties of some new triazene derivatives.
    Ionescu D; Neagu V; Dobre V; Niculescu-Duvaz I
    Neoplasma; 1981; 28(1):19-26. PubMed ID: 7279057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cluster analysis in the development of structure-activity relations for antitumor triazenes.
    Dunn WJ; Greenberg MJ; Callejas SS
    J Med Chem; 1976 Nov; 19(11):1299-301. PubMed ID: 1003406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships in antitumor aniline mustards.
    Panthananickal A; Hansch C; Leo A
    J Med Chem; 1978 Jan; 21(1):16-26. PubMed ID: 619146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential antitumor agents. 14. Acridylmethanesulfonanilides.
    Cain BF; Seelye RN; Atwell GJ
    J Med Chem; 1974 Sep; 17(9):922-30. PubMed ID: 4415157
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of triazines as inhibitors of L1210 dihydrofolate reductase and of L1210 cells sensitive and resistant to methotrexate.
    Selassie CD; Strong CD; Hansch C; Delcamp TJ; Freisheim JH; Khwaja TA
    Cancer Res; 1986 Feb; 46(2):744-56. PubMed ID: 3940640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies on the chemical stability and therapeutic effectiveness of water-insoluble 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) and its water-soluble hydrochloride against L1210 mouse leukemia.
    Woodman RJ; Kline I; Field RB; Gang M
    Cancer Chemother Rep; 1973; 57(4):383-91. PubMed ID: 4762437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.